B. Riley raised the firm’s price target on Verastem (VSTM) to $9 from $7 and keeps a Buy rating on the shares after speaking with management. The firm came away incrementally more positive on the stock, driven by the company’s recent progress and upcoming catalysts. Riley cites stronger near-term visibility and its recent analysis of publicly available data for G12D inhibitors for the target bump.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- RBC Capital reiterates Outperform after Verastem formalizes key 2025 priorities
- Verastem Expands Oncology Pipeline with VS-7375 Acquisition
- Verastem Appoints Matthew E. Ros as COO
- Verastem appoints Matthew Ros as COO
- Verastem exercises early option to license VS-7375 from GenFleet Therapeutics